Clinical Study
Rosiglitazone and Fenofibrate Additive Effects on Lipids
Table 1
Baseline characteristics and laboratory findings with posttreatment changes.
| Group | Placebo | Fenofibrate | Rosiglitazone | Combined | ANOVA | | | | | Rank | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | -value |
| Age | | | | | | M : F | 6 : 4 | 3 : 6 | 5 : 3 | 3 : 4 | |
| Pre-TG | | | | | | Post-TG | | | | | (%Δ) | | | | |
| Pre-HDL-C | | | | | | Post-HDL-C | | | | | (%Δ) | | | | |
| Pre-LDL-C | | | | | | Post-LDL-C | | | | | (%Δ) | | | | |
| ± pre-Tot C | | | | | | Post-Tot C | | | | | (%Δ) | | | | |
|
|